What is Josamycin Drugs Market?
Josamycin is a macrolide antibiotic. Its chemical name is "3-Acetate-4B- (3-methyl butanoate) leukomycin V". The compound is also available as propionate. The compound is derived from actinomycetes Streptomyces narbonensis var. Josamyceticus. Josamycin is used to treat infections of the upper respiratory tract and ENT organs (such as pharyngitis, tonsillitis, paratonsillitis, otitis media, sinusitis, laryngitis), diphtheria, scarlatina, lower respiratory tract infections (such as acute bronchitis, bronchopneumonia). Pneumonia, including atypical forms, whooping cough, psittacosis), oral infections (such as gingivitis and periodontal disease), skin and soft tissue infections (such as pyoderma, boils, anthrax, erysipelas, acne, lymphangitis, lymphadenitis), infections of the urinary tract and genital organs (such as Urethritis, prostatitis, gonorrhea, syphilis, sexual lymphogranuloma), chlamydia, mycoplasma (such as ureaplasma), and mixed urinary tract and genital infections. Josamycin has been on the list of vital and essential drugs since 2012. Josamycin, as most of the antibiotics used in the therapy of various infectious diseases, has many serious disadvantages, which are caused by the low selectivity of the action and, consequently, by the increased toxicity. When the drug is introduced into the body, only a small part of it gets to the target organ or cell. A significant part of the injected drug undergoes biotransformation without showing any antibacterial activity. In this connection, there is a need to introduce an excessive amount of the antibiotic, which leads to serious toxic effects. From the organs of the digestive tract: loss of appetite, nausea, heartburn, vomiting, dysbacteriosis, and diarrhea, flatulence, coated tongue, abdominal cramps, abnormal liver function, temporary increase in the activity of liver transaminase (AST, ALT), impaired bile discharge and jaundice. Others: swelling of the feet, temporary dose-dependent hearing loss, candidiasis, allergic skin reactions (hives, rash), and very rarely fever and general malaise.
The market study is being classified by Type (Coated Tablets (500 mg), Dispersible Tablets (1 G) and Suspension (in 5 ml - 150 mg)), by Application (Upper & Lower Respiratory Tract Infection, Diphtheria, Scarlatina, Oral Infections and Others) and major geographies with country level break-up.
Dragenopharm (United States), Bayer (Italy), Astellas (Italy), Ferrer International (Spain), BioChemPartner (China), Sandoz (Austria), Guangzhou Tosun Pharmaceutical Ltd. (China), Sine Pharmaceutical (China), SAJA Pharma (Saudi Arabia), Guilin Pharma (China), CSPC Pharmaceutical Group Limited (China) and Guanghua Pharma (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Minsheng Pharma (China) and Suzhou No.1 Pharm (China).
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Chinese Players will contribute to the maximum growth of Global Josamycin Drugs market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Josamycin Drugs market by Type, Application and Region.
On the basis of geography, the market of Josamycin Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Rising in Prevalence of Infectious Diseases across the Globe
- Increase in Demand for Antibiotics, owing to Increased Consumption in Low- and Middle-Income Countries
- Increased Prevalence of Diseases such as COVID-19
- Increased Number of Diagnostics Centres and Hospitals
- The Rise in the Government Funding for Research and Development
- Increasing Awareness among People about Preventive Healthcare
- Growing Demand from Online Customers
- Development of Novel Approaches to Treat Bacterial Infections
- Stringent Government Rules and Regulations
- Growth in the Healthcare Industry
- Increased Research and Development Activities
- A Rise in the Online Pharmacies
- Novel Combination Therapies to Treat Various Microbial Infections
- Several Side Effect Occurs due to High Consumption of the Drug
Key Target AudienceManufacturers of Josamycin Drugs, Suppliers and Distributors of Josamycin Drugs, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase